Abu Dhabi’s sovereign wealth fund ADQ has taken a significant step towards becoming a leader in the life sciences sector with the launch of Arcera. This new healthcare company consolidates its pharmaceutical interests in Switzerland, Turkey, and Egypt, making it one of the region’s largest life sciences businesses. 

To be based in Abu Dhabi, Arcera aims to accelerate growth and drive innovation.

This strategic move aligns with the UAE’s 2030 Healthcare Life Sciences Vision, bolstering the nation’s position at the forefront of scientific and technological advancements. 

Arcera brings together three established companies — Acino International (Switzerland), Birgi Mefar Group (Turkey), and Amoun Pharmaceutical Company (Egypt) — and has a portfolio of 2,000 branded medicines across various therapeutic areas, addressing many acute and chronic conditions. 

Isabel Afonso, appointed CEO of Arcera, said the company will allow them “to pursue bold ambitions and become a leading global life sciences company fostering longer and healthier lives.” 

Arcera has set ambitious targets for the future. It plans to double revenue through strategic acquisitions and partnerships within five years and become a preferred partner for academic institutions and leading pharmaceutical companies. 

By leveraging Abu Dhabi’s advanced technologies and research capabilities, it aims to unlock breakthroughs in life sciences.

The Innovation By Design Summit is in Doha on April 24. Attendance at the summit is by invitation only. Delegates can register here to receive their exclusive invite.